Funded Projects › HORIZON
MC4DD · Macrocycles for Drug Discovery
Better drugs are one of the most efficient and sustainable ways to improve health care, a key strategic orientation in Horizon Europe.New drug modalities such as macrocycles are expected to be a key enabling technology for this strategic perspective. The goal of MC4DD is to train the next generation of European medicinal chemists in a multidisciplinary environment to promote European drug discovery competitiveness, directly by advancing knowhow on macrocycles and long-term via the skills carried on by the researchers trained in the doctoral network.
Consortium · 20 organisations
TECHNISCHE UNIVERSITAT DARMSTADT
DE · €521,078
ANALYTICON DISCOVERY GMBH
DE
ABBVIE DEUTSCHLAND GMBH & CO KG
DE · €260,539
UNIVERSITEIT LEIDEN
NL · €274,370
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
UK
SANOFI-AVENTIS DEUTSCHLAND GMBH
DE · €260,539
FIDELTA DOO ZA ISTRAZIVANJE I RAZVOJ
HR
UKRORGSYNTEZ LTD
UA · €260,539
ASTRAZENECA AB
SE · €293,710
UNIVERSITA DEGLI STUDI DI TORINO
IT · €518,875
F. HOFFMANN-LA ROCHE AG
CH
UPPSALA UNIVERSITET
SE · €881,129
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE
CH
UNIVERSITY OF YORK
UK
Bayer AG
DE
ENAMINE GERMANY GMBH
DE
EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH
CH
JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAIN
DE
UNIVERSITY COLLEGE LONDON
UK
NOVO NORDISK A/S
DK
← Find collaborators and more funded projects
Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.